AstraZeneca Covid-19 vaccine trial on hold over safety concern – STAT News

Anil Panchal FXStreet

Early Wednesday morning in Asia, global markets got another blow to the risk-tone sentiment as AstraZeneca halts the phase 3 trials for the coronavirus (COVID-19) vaccine citing a suspected serious adverse reaction in a participant in the United Kingdom, per STAT news.

Key quotes

A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the company’s ‘standard review process triggered a pause to vaccination to allow review of safety data.’

It was not immediately clear who placed the hold on the trial, though it is possible it was placed voluntarily by AstraZeneca and not ordered by any regulatory agency.

The nature of the adverse reaction and when it happened were also not immediately known, though the participant is expected to recover, according to an individual familiar with the matter.

The spokesperson described the pause as ‘a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.’

The spokesperson also said that the company is ‘working to expedite the review of the single event to minimize any potential impact on the trial timeline.’

FX implications

While portraying the risk aversion wave, S&P 500 Futures drop 0.60% to 3,314 by the press time.

Author

Anil Panchal

FXStreet

Anil Panchal has nearly 15 years of experience in tracking financial markets. With a keen interest in macroeconomics, Anil aptly tracks global news/updates and stays well-informed about the global financial moves and their implications.

GBP/USD gains traction above 1.3400 as markets bet on BoE rate hikes

The GBP/USD pair gathers strength to around 1.3430 during the Asian trading hours on Friday. The British Pound edges higher against the US Dollar on the UK government leadership transition and growing expectations of further Bank of England interest rate hikes.

EUR/USD nudges higher above 1.1400 as traders ramp up their bets on ECB hikes

The EUR/USD pair posts modest gains around 1.1430 during the early Asian session on Friday, bolstered by a softer US Dollar. The European Central Bank is grappling with elevated core inflation, forcing traders to price in more aggressive tightening despite mixed guidance from ECB officials.

Gold hovers below $4,150 amid subdued USD price action

Gold struggles to capitalize on the previous day's positive move, holding below $4,150 in the Asian session on Friday as traders await further developments surrounding the US-Iran saga. Less hawkish FOMC Minutes keep the US Dollar on the defensive and help cap any downside in the non-yielding yellow metal.

Stocks rise as chipmakers rally and Iran oil shock fears fade

Stocks found their footing because two different pressure valves opened at the same time. Oil eased as traders faded the worst-case Iran script, while chipmakers caught a separate gust of oxygen from inside the AI ecosystem itself. That distinction matters. Crude helped calm the macro room, but it was not the spark under semis.

Five sessions, one round trip: Why the whipsaw is exactly what Warsh ordered

Markets opened July with a December hike as the base case and spent five trading sessions unlearning and relearning it. A 57K payrolls print bled the tightening bets out of the strip; a re-shut Strait of Hormuz is pushing them back in. Wednesday's minutes from the June Federal Open Market Committee meeting landed mid-round-trip, describing a world that had already stopped existing.

Bye, forward guidance: How to trade when central banks choose silence

Central banks have spent years telling markets what might come next. Now, traders face the possibility that they say a lot less. From the Federal Reserve to the European Central Bank and the Bank of England, policymakers are pushing back against forward guidance.